Literature DB >> 23845844

Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning.

Weili Wang1, Yaping Xu, Matthew Schipper, Martha M Matuszak, Timothy Ritter, Yue Cao, Randall K Ten Haken, Feng-Ming Spring Kong.   

Abstract

PURPOSE: This study aimed to compare lung dose-volume histogram (DVH) parameters such as mean lung dose (MLD) and the lung volume receiving ≥20 Gy (V20) of commonly used definitions of normal lung in terms of tumor/target subtraction and to determine to what extent they differ in predicting radiation pneumonitis (RP). METHODS AND MATERIALS: One hundred lung cancer patients treated with definitive radiation therapy were assessed. The gross tumor volume (GTV) and clinical planning target volume (PTVc) were defined by the treating physician and dosimetrist. For this study, the clinical target volume (CTV) was defined as GTV with 8-mm uniform expansion, and the PTV was defined as CTV with an 8-mm uniform expansion. Lung DVHs were generated with exclusion of targets: (1) GTV (DVHG); (2) CTV (DVHC); (3) PTV (DVHP); and (4) PTVc (DVHPc). The lung DVHs, V20s, and MLDs from each of the 4 methods were compared, as was their significance in predicting radiation pneumonitis of grade 2 or greater (RP2).
RESULTS: There are significant differences in dosimetric parameters among the various definition methods (all Ps<.05). The mean and maximum differences in V20 are 4.4% and 12.6% (95% confidence interval 3.6%-5.1%), respectively. The mean and maximum differences in MLD are 3.3 Gy and 7.5 Gy (95% confidence interval, 1.7-4.8 Gy), respectively. MLDs of all methods are highly correlated with each other and significantly correlated with clinical RP2, although V20s are not. For RP2 prediction, on the receiver operating characteristic curve, MLD from DVHG (MLDG) has a greater area under curve of than MLD from DVHC (MLDC) or DVHP (MLDP). Limiting RP2 to 30%, the threshold is 22.4, 20.6, and 18.8 Gy, for MLDG, MLDC, and MLDP, respectively.
CONCLUSIONS: The differences in MLD and V20 from various lung definitions are significant. MLD from the GTV exclusion method may be more accurate in predicting clinical significant radiation pneumonitis. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23845844      PMCID: PMC4028143          DOI: 10.1016/j.ijrobp.2013.05.003

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  20 in total

Review 1.  Tolerance of normal tissue to therapeutic irradiation.

Authors:  B Emami; J Lyman; A Brown; L Coia; M Goitein; J E Munzenrider; B Shank; L J Solin; M Wesson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1991-05-15       Impact factor: 7.038

Review 2.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  The impact of heterogeneity correction on dosimetric parameters that predict for radiation pneumonitis.

Authors:  Daniel T Chang; Kenneth R Olivier; Christopher G Morris; Chihray Liu; James F Dempsey; Rashmi K Benda; Jatinder R Palta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-01-19       Impact factor: 7.038

4.  Adding ipsilateral V20 and V30 to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy.

Authors:  Sara Ramella; Lucio Trodella; Tommaso Claudio Mineo; Eugenio Pompeo; Gerardina Stimato; Diego Gaudino; Vincenzo Valentini; Francesco Cellini; Marzia Ciresa; Michele Fiore; Angelo Piermattei; Patrizia Russo; Alfredo Cesario; Rolando M D'Angelillo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

5.  Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis.

Authors:  Feng-Ming Kong; James A Hayman; Kent A Griffith; Gregory P Kalemkerian; Douglas Arenberg; Susan Lyons; Andrew Turrisi; Allen Lichter; Benedick Fraass; Avraham Eisbruch; Theodore S Lawrence; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-02       Impact factor: 7.038

6.  Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer.

Authors:  J Armstrong; A Raben; M Zelefsky; M Burt; S Leibel; C Burman; G Kutcher; L Harrison; C Hahn; R Ginsberg; V Rusch; M Kris; Z Fuks
Journal:  Radiother Oncol       Date:  1997-07       Impact factor: 6.280

7.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

Authors:  M V Graham; J A Purdy; B Emami; W Harms; W Bosch; M A Lockett; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

8.  Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer.

Authors:  Tae Hyun Kim; Kwan Ho Cho; Hong Ryull Pyo; Jin Soo Lee; Jae Ill Zo; Dae Ho Lee; Jong Mog Lee; Hyae Young Kim; Bin Hwangbo; Sung Yong Park; Joo Young Kim; Kyung Hwan Shin; Dae Yong Kim
Journal:  Radiology       Date:  2005-02-09       Impact factor: 11.105

9.  Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis.

Authors:  D Oetzel; P Schraube; F Hensley; G Sroka-Pérez; M Menke; M Flentje
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-09-30       Impact factor: 7.038

10.  Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis.

Authors:  M K Martel; R K Ten Haken; M B Hazuka; A T Turrisi; B A Fraass; A S Lichter
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-02-01       Impact factor: 7.038

View more
  17 in total

1.  Radiation-induced lung toxicity in non-small-cell lung cancer: Understanding the interactions of clinical factors and cytokines with the dose-toxicity relationship.

Authors:  Peter G Hawkins; Philip S Boonstra; Stephen T Hobson; Jason W D Hearn; James A Hayman; Randall K Ten Haken; Martha M Matuszak; Paul Stanton; Gregory P Kalemkerian; Nithya Ramnath; Theodore S Lawrence; Matthew J Schipper; Feng-Ming Spring Kong; Shruti Jolly
Journal:  Radiother Oncol       Date:  2017-09-23       Impact factor: 6.280

Review 2.  Nondosimetric risk factors for radiation-induced lung toxicity.

Authors:  Feng-Ming Spring Kong; Shulian Wang
Journal:  Semin Radiat Oncol       Date:  2014-12-15       Impact factor: 5.934

3.  Dosimetric evaluation of VMAT and helical tomotherapy techniques comparing conventional volumes with clinical target volumes based on new ESTRO ACROP post-mastectomy with immediate implant reconstruction contouring guidelines.

Authors:  Evren Ozan Göksel; Evrim Tezcanli; Alptekin Arifoğlu; Halil Küçücük; Öznur Şenkesen; Ufuk Abacıoğlu; Işık Aslay; Meriç Şengöz
Journal:  Radiat Oncol       Date:  2022-10-21       Impact factor: 4.309

4.  CREB pathway links PGE2 signaling with macrophage polarization.

Authors:  Bing Luan; Young-Sil Yoon; John Le Lay; Klaus H Kaestner; Susan Hedrick; Marc Montminy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-07       Impact factor: 11.205

5.  Normal lung tissue complication probability in MR-Linac and conventional radiotherapy.

Authors:  Somayeh Gholami; Francesco Longo; Sara Shahzadeh; Hassan Ali Nedaie; Ryan Sharp; Ali S Meigooni
Journal:  Rep Pract Oncol Radiother       Date:  2020-09-29

6.  Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.

Authors:  Zhicheng Jiao; Hongming Li; Ying Xiao; Charu Aggarwal; Maya Galperin-Aizenberg; Daniel Pryma; Charles B Simone; Steven J Feigenberg; Gary D Kao; Yong Fan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2021-01-19       Impact factor: 7.038

7.  A novel nomogram containing acute radiation esophagitis predicting radiation pneumonitis in thoracic cancer receiving radiotherapy.

Authors:  Wenjie Tang; Xiaolin Li; Haining Yu; Xiaoyang Yin; Bing Zou; Tingting Zhang; Jinlong Chen; Xindong Sun; Naifu Liu; Jinming Yu; Peng Xie
Journal:  BMC Cancer       Date:  2021-05-22       Impact factor: 4.430

Review 8.  Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Authors:  Feng-Ming Spring Kong; Vitali Moiseenko; Jing Zhao; Michael T Milano; Ling Li; Andreas Rimner; Shiva Das; X Allen Li; Moyed Miften; ZhongXing Liao; Mary Martel; Soren M Bentzen; Andrew Jackson; Jimm Grimm; Lawrence B Marks; Ellen Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 8.013

9.  A situational awareness Bayesian network approach for accurate and credible personalized adaptive radiotherapy outcomes prediction in lung cancer patients.

Authors:  Yi Luo; Shruti Jolly; David Palma; Theodore S Lawrence; Huan-Hsin Tseng; Gilmer Valdes; Daniel McShan; Randall K Ten Haken; Issam Ei Naqa
Journal:  Phys Med       Date:  2021-06-04       Impact factor: 3.119

10.  To gate or not to gate - dosimetric evaluation comparing Gated vs. ITV-based methodologies in stereotactic ablative body radiotherapy (SABR) treatment of lung cancer.

Authors:  Joshua Kim; Qixue Wu; Bo Zhao; Ning Wen; Munther Ajlouni; Benjamin Movsas; Indrin J Chetty
Journal:  Radiat Oncol       Date:  2016-09-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.